CN112843336A - Nanoparticles and gel for promoting dentin regeneration and preparation method and application thereof - Google Patents

Nanoparticles and gel for promoting dentin regeneration and preparation method and application thereof Download PDF

Info

Publication number
CN112843336A
CN112843336A CN202110240117.7A CN202110240117A CN112843336A CN 112843336 A CN112843336 A CN 112843336A CN 202110240117 A CN202110240117 A CN 202110240117A CN 112843336 A CN112843336 A CN 112843336A
Authority
CN
China
Prior art keywords
azd
chitosan
preparation
cyclodextrin
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110240117.7A
Other languages
Chinese (zh)
Other versions
CN112843336B (en
Inventor
周建
王松灵
王玉记
张晨
胡磊
贾翌江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Medical University
Beijing Stomatological Hospital
Original Assignee
Capital Medical University
Beijing Stomatological Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Medical University, Beijing Stomatological Hospital filed Critical Capital Medical University
Priority to CN202110240117.7A priority Critical patent/CN112843336B/en
Publication of CN112843336A publication Critical patent/CN112843336A/en
Application granted granted Critical
Publication of CN112843336B publication Critical patent/CN112843336B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/12Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Abstract

The invention provides a nano-particle and a gel for promoting dentin regeneration as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The AZD 2858-CD-chitosan nanoparticle for promoting the regeneration of dentin is prepared by taking diluent of stock solution containing AZD2858 and chitosan as raw materials, and the prepared AZD 2858-CD-chitosan nanoparticle can promote the migration of deciduous papilla stem cells of apical teeth, the differentiation of odontoblasts and the development and regeneration of dental tissues. The invention also prepares AZD 2858-CD-chitosan gel based on the AZD 2858-CD-chitosan nano particles, is a sustained-release preparation, is filled in an experimental animal model, has the activity of promoting dentin regeneration, has obvious superiority in dental pulp tissue engineering, and has huge application market in the development and regeneration of dental tissues.

Description

Nanoparticles and gel for promoting dentin regeneration and preparation method and application thereof
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to nanoparticles and gel for promoting dentin regeneration, and a preparation method and application thereof.
Background
The dental pulp infectious diseases such as the dental pulp disease, the periapical disease and the like are the most common oral diseases, the prevalence rate is high, the affected age span is large, even the loss of teeth can be caused, and the oral cavity and the whole body health of a patient are seriously affected[1]. Currently, the main method for clinical treatment of endodontic and periapical diseases is root canal therapy. This method has difficulties in completely removing bacteria from the root canal and in completely tightly filling the root canal due to the fact that bacteria can colonize the dentinal tubules and the complex anatomy of the root canal system. In recent years, the total clinical success rate of root canal therapy is 78-98%[2]. In addition, root canal therapy is an ablative therapy of dental pulp and its outer dentin, and the dental pulp and its outer dentin are closely related anatomically and functionally to constitute a dental pulp-dentin complex, and exert important physiological functions of responding to external stimuli, promoting restorative dentin formation, regulating root development, maintaining homeostasis of teeth, and the like[3]. After the endodontic treatment and the removal of the dental pulp and dentin complex, the tooth has no longer functions of immune protection, external stimulation sensing, self-restoration and the like, and the risk of secondary infection and dental fissure is increased[4]. The root apex of the young permanent tooth is not completely developed, the root canal orifice is open, the wall of the root canal is thin, the root canal therapy can not effectively carry out the root canal preparation and filling, can not promote the normal completion development of the root canal, and the probability of the complications such as too short root of the tooth, tooth breakage and the like is increased, and the long-term curative effect is not ideal[4-5]. Therefore, based on fully understanding the process and mechanism of development, regeneration and restoration of dental pulp dentin complex, tissue engineering and regenerative medicine means are utilizedIn the root canal for strictly controlling infection, the dental pulp regeneration treatment aiming at the dental pulp dentin complex with complete in-situ regeneration tissue structure and normal physiological function is the development direction and inevitable trend of the treatment of dental pulp infectious diseases, and has become one of the hot points of the oral medical research.
Reference documents:
[1] the material is plain, dental endodontics, fourth edition, Beijing: people health press, 2010.
[2]Ng YL,Mann V,Gulabivala K.Tooth survival following non-surgical root canal treatment:a systematic review of the literature.Int Endo J,2010,43(3):171-189.
[3]Kim SG,Zhou J,Solomon C,et al.Effects of growth factors on dental stem/progenitor cells.Dent Clin North Am.2012,56,563-75.
[4] Liu Da Yong, Humeilin, pulp regeneration strategy in microenvironment and research progress, journal of International biomedical engineering, 2019,42(1):71-77.
[5]Dammaschke T,Steven D,Kaup M,et al.Long-term survival of root-canal-treated teeth:a retrospective study over 10years.J Endod,2003,29(10):638-643.
Disclosure of Invention
In view of the above, the invention aims to provide nanoparticles and a gel for promoting dentin regeneration, and a preparation method and an application thereof, which can improve the accuracy, stability and operability of AZD2858 in inducing the homing of endogenous stem cells, prolong the acting time of AZD2858 in root canals and promote the exertion of biological effects.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a preparation method of AZD 2858-CD-chitosan nanoparticles for promoting dentin regeneration, which comprises the following steps: mixing the diluent of the stock solution containing AZD2858 with chitosan to obtain the AZD 2858-CD-chitosan nano-particles;
the concentration of AZD2858 in the diluent was 50 nM;
the stock solution also comprises a normal saline solution of DMSO and beta-cyclodextrin, and the volume ratio of the normal saline solution of DMSO to the normal saline solution of beta-cyclodextrin is 1 (9-19); the volume percentage of DMSO in the stock solution is 10% -5%, and the mass percentage of beta-cyclodextrin in the stock solution is 5% -25%;
the mass ratio of the volume of the diluent to the chitosan is 400 mul: 1-3 mg.
Preferably, the mass percentage of the beta-cyclodextrin in the physiological saline solution of the beta-cyclodextrin is 15-25%.
Preferably, the concentration of AZD2858 in the stock solution is 2.5 mM.
Preferably, the preparation method of the stock solution comprises the step of preparing AZD2858 into 2.5mM stock solution by taking a mixed solution as a solvent, wherein the mixed solution comprises DMSO with the volume percentage of 10% and a physiological saline solution of beta-cyclodextrin with the volume percentage of 90%, and the mass percentage of the beta-cyclodextrin in the physiological saline solution of the beta-cyclodextrin is 15-25%.
The invention also provides the AZD 2858-CD-chitosan nano-particles prepared by the preparation method.
The invention also provides AZD 2858-CD-chitosan gel prepared on the basis of the AZD 2858-CD-chitosan nanoparticle, wherein the mass ratio of the AZD 2858-CD-chitosan nanoparticle to the matrigel is (3-7): (7-3).
The invention also provides a preparation method of the AZD 2858-CD-chitosan gel, which comprises the following steps: mixing AZD 2858-CD-chitosan nano particles with matrigel to obtain AZD 2858-CD-chitosan gel; the mass ratio of the AZD 2858-CD-chitosan nanoparticles to the matrigel is (3-7): (7-3).
Preferably, the matrigel comprises Matrix Gel, shellac or pectin.
Preferably, the mass ratio of the AZD 2858-CD-chitosan nanoparticles to the matrigel is 5: 5.
The invention also provides the application of the AZD 2858-CD-chitosan nano-particles or the AZD 2858-CD-chitosan gel in preparing dental tissue development and/or regeneration reagents.
The invention provides a preparation method of AZD 2858-CD-chitosan nanoparticles for promoting dentin regeneration, which comprises the following steps: and mixing the diluent of the stock solution containing the AZD2858 with chitosan to obtain the AZD 2858-CD-chitosan nano-particles. The AZD 2858-CD-chitosan nano-particles prepared by the preparation method can promote the migration of deciduous head stem cells of the root tips, the differentiation of odontoblasts and the development and regeneration of dental tissues. The invention also prepares AZD 2858-CD-chitosan gel based on the AZD 2858-CD-chitosan nano particles, is a sustained release preparation, is filled in experimental animal models, verifies the activity of promoting dentin regeneration in animal experiments, has obvious superiority in dental pulp tissue engineering, and has huge application market in development and regeneration of dental tissues.
Drawings
FIG. 1 shows the morphology and cumulative release of AZD 2858-CD-chitosan gel, wherein A represents the uniform particle structure of AZD 2858-CD-chitosan nanoparticles with the diameter range of 150-200 nm; b represents AZD 2858-CD-chitosan nanoparticles: cumulative release of AZD2858 at a Matrix Gel ratio of 50: 50;
FIG. 2 shows that the SCAP migration ability of AZD2858 and AZD 2858-CD-chitosan nanoparticles is remarkably improved;
FIG. 3 is a diagram of dental pulp tissue successfully regenerated by AZD 2858-CD-chitosan @ Matrix Gel and human dental pulp stem cells, wherein A represents that dental pulp tissue regeneration is not seen in a blank control group; b shows the result of H & E staining, and AZD 2858-CD-chitosan @ Matrix Gel and human dental pulp stem cells can successfully induce the regeneration of dental pulp tissues.
Detailed Description
The invention provides a preparation method of AZD 2858-CD-chitosan nanoparticles for promoting dentin regeneration, which comprises the following steps: the concentration of AZD2858 in the diluent is 50-150 nM;
the stock solution also comprises a normal saline solution of DMSO and beta-cyclodextrin, and the volume ratio of the normal saline solution of DMSO to the normal saline solution of beta-cyclodextrin is 1 (9-19); the volume percentage of DMSO in the stock solution is 10% -5%, and the mass percentage of beta-cyclodextrin in the stock solution is 5% -25%;
the mass ratio of the volume of the diluent to the chitosan is 400 mu l: 1-3 mg.
Firstly, preparing AZD2858 (3-amino-6- [4- [ (4-methyl-1-piperazinyl) sulfonyl ] phenyl ] -N-3-pyridyl-pyrazinecarboxamide) into a stock solution of 2.5-7.5 mM, wherein the solvent of the stock solution is a mixed solution of a normal saline solution containing DMSO and beta-cyclodextrin; the volume ratio of DMSO to beta-cyclodextrin in the solvent is 1 (9-19), and preferably 1: 9. According to the invention, AZD2858 is dissolved by using the mixed solution and the stock solution with the concentration of 2.5-7.5 mM is prepared, in the embodiment of the invention, the mixed solution is preferably formed by mixing 10% (v/v) DMSO and 90% (v/v) beta-cyclodextrin physiological saline solution, and the beta-cyclodextrin content in the beta-cyclodextrin physiological saline solution is preferably 5-25% by mass. The method for producing the physiological saline solution of β -cyclodextrin of the present invention is not particularly limited, but in the examples, the ratio of β -cyclodextrin to physiological saline is preferably set to 1 g: 5mL of the beta-cyclodextrin solution is mixed according to the mass-volume ratio to prepare the physiological saline solution of 20 percent of beta-cyclodextrin. The AZD2858 of the present invention is preferably available from MCE reagents (MedChemExpress LLC 50mg package) and the beta-cyclodextrin is preferably available from MCE reagents (MedChemExpress LLC 1g package).
After a stock solution is obtained, diluting the stock solution to 50-150 nM by using a normal saline solution of the beta-cyclodextrin, and mixing the diluted solution with chitosan to obtain the AZD 2858-CD-chitosan nanoparticles; the volume mass ratio of the diluted solution to the chitosan is 400 mul: 1-3 mg. The preparation method of the diluted solution is not particularly limited in the present invention, and in the present embodiment, 25 μ l of the stock solution is preferably mixed with 975 μ l of the 20% cyclodextrin physiological saline solution to obtain a 50nM diluted solution. The present invention mixes the diluted solution with chitosan, preferably uniformly dispersed every 1.5mg of chitosan in 400. mu.l of 50nM solution, to obtain a solution containing AZD 2858-CD-chitosan nanoparticles.
The invention also provides the AZD 2858-CD-chitosan nano-particles prepared by the preparation method. The AZD 2858-CD-chitosan nanoparticle provided by the invention utilizes intermolecular hydrogen bonds and intermolecular van der Waals force to pack AZD2858 in CD, and then the CD is loaded into chitosan particles.
The invention also provides AZD 2858-CD-chitosan gel prepared on the basis of the AZD 2858-CD-chitosan nanoparticle, wherein the mass ratio of the AZD 2858-CD-chitosan nanoparticle to the matrigel is (3-7): (7-3).
The AZD 2858-CD-chitosan gel is in a solution state at 4 ℃ and in a gel state at 20-37 ℃, the concentration of AZD2858 in the AZD 2858-CD-chitosan gel is preferably 50nM, and the concentration of chitosan is preferably 3 mg/ml.
The invention also provides a preparation method of the AZD 2858-CD-chitosan gel, which comprises the following steps: mixing AZD 2858-CD-chitosan nano particles with matrigel to obtain AZD 2858-CD-chitosan gel; the mass ratio of the AZD 2858-CD-chitosan nanoparticles to the matrigel is (3-7): (7-3).
The matrigel provided by the invention preferably comprises Matrix Gel, shellac or pectin, and the matrigel is used as a support, and the combined action of the Matrix Gel and a nano drug delivery system is utilized, so that the pharmacokinetic effect of the matrigel can be optimized, and the AZD2858 can be controlled and released. The mass ratio of the AZD 2858-CD-chitosan nanoparticles to the matrigel is preferably 5:5, and at the moment, the AZD2858 can realize the optimal linear release effect within 3 weeks, and the cumulative release amount exceeds 92%. The source of the matrigel of the present invention is not particularly limited, and conventional commercially available reagents in the art may be used.
The nanoparticle and the gel for promoting dentin regeneration and the preparation method and application thereof provided by the present invention will be described in detail with reference to the following examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Preparation of AZD 2858-CD-chitosan nano-particles
1. 2g of beta-cyclodextrin was added to 10ml of physiological saline to prepare a 20% beta-cyclodextrin physiological saline solution.
2. 2.12mg of AZD2858 was weighed out and prepared into a 2.5mM stock solution using a mixed solution (10% DMSO + 90% physiological saline solution containing 20% beta-cyclodextrin).
3. Mu.l of stock solution + 975. mu.l of 20% beta-cyclodextrin in physiological saline was diluted to 50 nM.
4. 1.5mg of chitosan was weighed and dispersed in 400. mu.l of 50nM solution to obtain a solution containing AZD 2858-CD-chitosan nanoparticles. Dropping the solution on a mica sheet, volatilizing the solvent, and detecting under a scanning electron microscope, wherein the AZD 2858-CD-chitosan nano particles which are visible under the scanning electron microscope are uniform particle structures with the diameter range of 150-200 nm (A in figure 1).
Secondly, preparing AZD 2858-CD-chitosan @ Matrix Gel
To the above solution of 400. mu. LAZD 2858-CD-chitosan nanoparticles (containing AZD 2858-CD-chitosan 60mg) was added 100. mu. LMatrix Gel (BD Co., 10mL) to obtain AZD 2858-CD-chitosan @ Matrix Gel containing 50nM AZD2858 and 3mg/mL chitosan, AZD 2858-CD-chitosan: the mass ratio of Matrix Gel is 37.5: 62.5, the solution is at 4 ℃, and the jelly is at 20-37 ℃.
The formulations were prepared according to the proportions shown in table 1, with different AZD 2858-CD-chitosans: matrix Gel mass ratio, determining the release effect of AZD2858, and finding that the content of AZD 2858-CD-chitosan: at a Matrix Ge of 50:50, AZD2858 achieved the best linear release within 3 weeks, with cumulative release exceeding 92% (B in FIG. 1).
TABLE 1 formulation of AZD 2858-CD-chitosan to Matrix Gel
Figure BDA0002961880790000061
Example 2
Effect of AZD2858 and AZD-CD-Chitosan on the ability to migrate root apical papilla Stem Cells (SCAPs)
In vitro isolation and culture of SCAP according to cell density of 1 × 104And inoculating the strains/holes on an upper chamber of a transwell co-culture system, and respectively adding nonspecific regulatory bioactive factor Amelogenin (AML), AZD2858 and AZD 2858-CD-chitosan nanoparticles into a lower chamber of each group of co-culture systems. After 24h of culture, the migrated SCAPs are digested, collected and counted, and the result shows that the AZD2858 and AZD-CD 2858-chitosan nanoparticles can be obtainedRemarkably promotes the migration capability of SCAP, and no remarkable difference exists between AZD2858 and AZD 2858-CD-chitosan nanoparticle groups (figure 2).
Example 3
AZD 2858-CD-Chitosan @ Matrix Gel was transplanted into immunodeficient mouse balb/c (purchased from Wintolite laboratory animals Co.). Regenerated pulp tissue activity was tested according to the method of Dental pulp engineering with stem cells from ex-exerted devious tissue (M.M.Cordeiro, Z.Dong, T.Kaneko et al, "Dental pulp engineering with stem cells from ex-exerted devious tissue," Journal of endodynamics, vol.34, No.8, pp.962-969,2008):
AZD 2858-CD-chitosan @ Matrix Gel and human dental pulp stem cells were implanted back into the hypodermis of immunodeficient mice in a complex manner, and histological observation revealed that dental pulp tissue regeneration was locally visible (FIG. 3).
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.

Claims (10)

1. A preparation method of AZD 2858-CD-chitosan nanoparticles for promoting dentin regeneration is characterized by comprising the following steps: mixing the diluent of the stock solution containing AZD2858 with chitosan to obtain the AZD 2858-CD-chitosan nano-particles;
the concentration of AZD2858 in the diluent is 50-150 nM;
the stock solution also comprises a normal saline solution of DMSO and beta-cyclodextrin, and the volume ratio of the normal saline solution of DMSO to the normal saline solution of beta-cyclodextrin is 1 (9-19); the volume percentage of DMSO in the stock solution is 5-10%, and the mass percentage of beta-cyclodextrin in the stock solution is 5-25%;
the mass ratio of the volume of the diluent to the chitosan is 400 mu l: 1-3 mg.
2. The preparation method according to claim 1, wherein the beta-cyclodextrin is contained in the physiological saline solution of beta-cyclodextrin in an amount of 5 to 25% by mass.
3. The method according to claim 1, wherein the concentration of AZD2858 in the stock solution is 2.5 to 7.5 mM.
4. The preparation method according to claim 1 or 3, wherein the preparation method of the stock solution comprises the step of preparing AZD2858 into a 2.5mM stock solution by taking a mixed solution as a solvent, wherein the mixed solution comprises DMSO with a volume percentage of 10% and a physiological saline solution of beta-cyclodextrin with a volume percentage of 90%, and the mass percentage of the beta-cyclodextrin in the physiological saline solution of the beta-cyclodextrin is 5-25%.
5. AZD 2858-CD-chitosan nanoparticles prepared by the preparation method of any one of claims 1 to 4.
6. An AZD 2858-CD-chitosan gel prepared on the basis of the AZD 2858-CD-chitosan nanoparticles as claimed in claim 4, wherein the mass ratio of the AZD 2858-CD-chitosan nanoparticles to the matrigel is (3-7): (7-3).
7. A process for the preparation of AZD 2858-CD-chitosan gel according to claim 6, characterized in that it comprises the following steps: mixing AZD 2858-CD-chitosan nano particles with matrigel to obtain AZD 2858-CD-chitosan gel; the mass ratio of the AZD 2858-CD-chitosan nanoparticles to the matrigel is (3-7): (7-3).
8. The method of claim 7, wherein the matrigel comprises Matrix Gel, shellac, or pectin.
9. The preparation method according to claim 7, wherein the mass ratio of the AZD 2858-CD-chitosan nanoparticles to the matrigel is 5: 5.
10. Use of AZD 2858-CD-chitosan nanoparticles according to claim 5 or AZD 2858-CD-chitosan gel according to claim 6 in the preparation of a dental tissue development and/or regeneration agent.
CN202110240117.7A 2021-03-04 2021-03-04 Nanoparticles and gel for promoting dentin regeneration and preparation method and application thereof Active CN112843336B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110240117.7A CN112843336B (en) 2021-03-04 2021-03-04 Nanoparticles and gel for promoting dentin regeneration and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110240117.7A CN112843336B (en) 2021-03-04 2021-03-04 Nanoparticles and gel for promoting dentin regeneration and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN112843336A true CN112843336A (en) 2021-05-28
CN112843336B CN112843336B (en) 2022-10-25

Family

ID=75991607

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110240117.7A Active CN112843336B (en) 2021-03-04 2021-03-04 Nanoparticles and gel for promoting dentin regeneration and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN112843336B (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070248675A1 (en) * 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
CN101099728A (en) * 2007-07-26 2008-01-09 复旦大学 Mucosa adhesion nanometer particle-aquagel membrane drug delivery system and preparation method thereof
CN101217947A (en) * 2005-06-02 2008-07-09 圣地亚哥联合大学 Nanoparticles comprising chitosan and cyclodextrin
WO2013150193A1 (en) * 2012-04-06 2013-10-10 Centre National De La Recherche Scientifique Microparticles and nanoparticles made up of hydrophobized polysaccharides and an alpha-cyclodextrine
WO2016198238A1 (en) * 2015-06-11 2016-12-15 Commissariat à l'énergie atomique et aux énergies alternatives Material comprising a polymer capable of forming a hydrogel and nanoparticles
CN110114048A (en) * 2016-10-21 2019-08-09 伦敦国王学院 Dental treatment
WO2020194034A1 (en) * 2019-03-27 2020-10-01 Universidad De Chile Nanoparticle of chitosan and cyclodextrin containing encapsulated interferon and pharmaceutical compositions that contain it

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217947A (en) * 2005-06-02 2008-07-09 圣地亚哥联合大学 Nanoparticles comprising chitosan and cyclodextrin
US20070248675A1 (en) * 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
CN101099728A (en) * 2007-07-26 2008-01-09 复旦大学 Mucosa adhesion nanometer particle-aquagel membrane drug delivery system and preparation method thereof
WO2013150193A1 (en) * 2012-04-06 2013-10-10 Centre National De La Recherche Scientifique Microparticles and nanoparticles made up of hydrophobized polysaccharides and an alpha-cyclodextrine
WO2016198238A1 (en) * 2015-06-11 2016-12-15 Commissariat à l'énergie atomique et aux énergies alternatives Material comprising a polymer capable of forming a hydrogel and nanoparticles
CN110114048A (en) * 2016-10-21 2019-08-09 伦敦国王学院 Dental treatment
WO2020194034A1 (en) * 2019-03-27 2020-10-01 Universidad De Chile Nanoparticle of chitosan and cyclodextrin containing encapsulated interferon and pharmaceutical compositions that contain it

Also Published As

Publication number Publication date
CN112843336B (en) 2022-10-25

Similar Documents

Publication Publication Date Title
Li et al. Porous chitosan bilayer membrane containing TGF-β1 loaded microspheres for pulp capping and reparative dentin formation in a dog model
Demarco et al. Dental pulp tissue engineering
Sun et al. Biological approaches toward dental pulp regeneration by tissue engineering
CN113318274B (en) Hydrogel and preparation method and application thereof
JP2012530548A (en) Tooth scaffolding
Liu et al. Biomaterial scaffolds for clinical procedures in endodontic regeneration
CN103330680A (en) Nano drug transdermal preparation and preparation method thereof
CN113577366B (en) Dry film dressing for promoting rapid healing of difficult-to-heal wounds of diabetes and preparation method thereof
Zhang et al. Bilayered PLGA/wool keratin composite membranes support periodontal regeneration in beagle dogs
JP5514110B2 (en) Tooth defect restoration method and restoration material manufacturing method
Grawish et al. Challenges of engineering biomimetic dental and paradental tissues
Liu et al. Immunomodulatory effect of dimethyloxallyl glycine/nanosilicates-loaded fibrous structure on periodontal bone remodeling
WO2022111595A1 (en) Core-shell microgel, oxygen sustained-release material, drug sustained-release formulation and multifunctional cell encapsulation system
CN113621570A (en) Tissue engineering dental pulp based on digital optical processing printing technology and preparation method
CN104288093B (en) Application of the nano drug transdermal preparation in tumour
Lee et al. Advances in research on stem cell-based pulp regeneration
CN112843336B (en) Nanoparticles and gel for promoting dentin regeneration and preparation method and application thereof
Mallishery et al. Regenerative endodontics–looking inward
Cao et al. Tissue engineering in stomatology: a review of potential approaches for oral disease treatments
WO2021087179A1 (en) Periodontal micropatch and uses thereof
Chen et al. Effects of restorative materials on dental pulp stem cell properties
Dan et al. Synergistic approach of graphene oxide-silver-titanium nanocomposite film in oral and dental studies: A new paradigm of infection control in dentistry
Münchow et al. Current and future views on biomaterial use in regenerative endodontics
CN111388761B (en) Application of gastrodin in medical titanium metal use in diabetes environment
CN103169951B (en) Gel microcapsule with cell recruitment function and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant